Gino Santini

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.

ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ.

Enalare Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies for patients with life-threatening acute respiratory and critical care conditions, such as community drug overdose, post-operative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, NJ. Enalare maintains rights to its novel compounds and intends to start additional clinical trials with ena-001 for several indications in the near term. The company was founded by Joseph V. Pergolizzi and is currently led by CEO Herm Cukier.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.

Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.